1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Biosimilars Market – by Disease Indication

1.3.2        North America Biosimilars Market – by Drug class

1.3.3        North America Biosimilars Market – by Route of Administration

1.3.4        North America Biosimilars Market – by End User

1.3.5        North America Biosimilars Market – by Country

2.           North America Biosimilars Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Biosimilars Market – Market Landscape

4.1         Overview

4.2         North America PEST Analysis

4.3         Expert’s Opinion

5.           North America Biosimilars Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing Prevalence of Chronic Diseases

5.1.2        Cost Effectiveness of Biosimilar Drugs

5.1.3        Rising Approvals of Biosimilars

5.2         Market Restraints

5.2.1        High-Cost Involvement and Complexities in Biosimilar Product Manufacturing

5.3         Market Opportunities

5.3.1        Patent Expiry of Blockbuster Biologics

5.4         Future Trend

5.4.1        Collaborations for Biosimilars and Clinical Trials

5.5         Impact analysis

6.           Biosimilars Market – North America Analysis

6.1         North America Biosimilars Market Revenue Forecast and Analysis

7.           North America Biosimilars Market – Revenue and Forecast to 2028 – by Disease Indication

7.1         Overview

7.2         North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

7.3         Cancer

7.3.1        Overview

7.3.2        Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.4         Diabetes

7.4.1        Overview

7.4.2        Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5         Autoimmune Diseases

7.5.1        Overview

7.5.2        Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.3        Psoriasis:

7.5.3.1          Overview

7.5.3.2          Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.4        Arthritis:

7.5.4.1          Overview

7.5.4.2          Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.5        Others:

7.5.5.1          Overview

7.5.5.2          Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.6         Others Disease Indications

7.6.1        Overview

7.6.2        Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.           North America Biosimilars Market Analysis and Forecast to 2028 – by Drug Class

8.1         Overview

8.2         North America Biosimilars Market, by Drug class 2021 & 2028 (%)

8.3         Granulocyte colony-stimulating factors

8.3.1        Overview

8.3.2        Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.4         Insulin

8.4.1        Overview

8.4.2        Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.5         TNF Blockers and Monoclonal Antibodies

8.5.1        Overview

8.5.2        TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.6         Others

8.6.1        Overview

8.6.2        Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.           North America Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration

9.1         Overview

9.2         North America Biosimilars Market, by Application 2021 & 2028 (%)

9.3         Intravenous

9.3.1        Overview

9.3.2        Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.4         Subcutaneous

9.4.1        Overview

9.4.2        Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.5         Others

9.5.1        Overview

9.5.2        Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.        North America Biosimilars Market – Revenue and Forecast to 2028 – by End User

10.1      Overview

10.2      North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

10.3      Hospitals

10.3.1     Overview

10.3.2     Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.4      Specialty Clinics

10.4.1     Overview

10.4.2     Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.5      Homecare

10.5.1     Overview

10.5.2     Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.6      Other

10.6.1     Overview

10.6.2     Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.        North America Biosimilars Market – Revenue and Forecast to 2028 – Country Analysis

11.1      Overview

11.1.1.1       US: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1       Overview

11.1.1.1.2       US: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3       US: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.1.3.1     US: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.1.4       US: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.1.5       US: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.1.6       US: Biosimilar Market, by End User, 2019–2028 (US$ Million)

11.1.1.2       Canada: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1       Canada: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.2       Canada: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.2.2.1     Canada: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.2.3       Canada: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.2.4       Canada: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.2.5       Canada: Biosimilar Market, by End User, 2019–2028 (US$ Million)

11.1.1.3       Mexico: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1       Mexico: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.2       Mexico: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.3.2.1     Mexico: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.3.3       Mexico: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.3.4       Mexico: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.3.5       Mexico: Biosimilar Market, by End User, 2019–2028 (US$ Million)

12.        Biosimilars Market – Industry Landscape

12.1      Overview

12.2      Growth Strategies in the Biosimilars Market

12.3      Inorganic Growth Strategies

12.3.1     Overview

12.4      Organic Growth Strategies

12.4.1     Overview

13.        Company Profiles

13.1      Amgen Inc

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Celltrion Inc

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Sanofi SA

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Biocon Ltd

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Coherus BioSciences Inc

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Eli Lilly and Co

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7      Sandoz AG

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Teva Pharmaceutical Industries Ltd

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

13.9      Pfizer Inc

13.9.1     Key Facts

13.9.2     Business Description

13.9.3     Products and Services

13.9.4     Financial Overview

13.9.5     SWOT Analysis

13.9.6     Key Developments

13.10   Dr. Reddy's Laboratories Ltd

13.10.1  Key Facts

13.10.2  Business Description

13.10.3  Products and Services

13.10.4  Financial Overview

13.10.5  SWOT Analysis

13.10.6  Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             Comparison Between Different Drug Developments

Table 2.             US Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 3.             US Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 4.             US Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 6.             US Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Canada Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Canada Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Canada Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Canada Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Canada Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Mexico Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Mexico Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Mexico Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Mexico Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Mexico Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Recent Inorganic Growth Strategies in the Biosimilars Market

Table 18.          Recent Organic Growth Strategies in the Biosimilars Market

Table 19.          Glossary of Terms

LIST OF FIGURES

Figure 1.           North America Biosimilars Market Segmentation

Figure 2.           North America Biosimilars Market, by Country

Figure 3.           North America Biosimilars Market Overview

Figure 4.           Cancer Segment Held Largest Share of Type Segment in North America Biosimilars Market

Figure 5.           US is Expected to Show Remarkable Growth During Forecast Period

Figure 6.           North America: PEST Analysis

Figure 7.           Experts’ Opinion

Figure 8.           North America Biosimilars Market Impact Analysis of Drivers and Restraints

Figure 9.           North America Biosimilars Market – Revenue Forecast and Analysis – 2020–2028

Figure 10.        North America Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

Figure 11.        Cancer: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        Diabetes: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Psoriasis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        Arthritis: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Others Disease Indications: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        North America Biosimilars Market, by Drug class 2021 & 2028 (%)

Figure 19.        Granulocyte colony-stimulating factors Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Insulin Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        TNF Blockers and Monoclonal Antibodies Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        Others Drug class: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        North America Biosimilars Market, by Application 2021 & 2028 (%)

Figure 24.        Intravenous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Subcutaneous: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        Others: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        North America Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

Figure 28.        Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        Homecare: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        Other: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        North America: Biosimilar Market, by Key Country – Revenue (2022) (US$ Million)

Figure 33.        North America: Biosimilar Market, by Country, 2021 & 2028 (%)

Figure 34.        US Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 35.        Canada Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 36.        Mexico Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 37.        Growth Strategies in the Biosimilars Market